The UK government has signalled that they want patients in the UK to receive access to innovative therapies quicker than historical timelines in key areas that align to national health priorities such as Neurological conditions, Rare diseases and Oncology. To aid this they have invested over £10 million to support the MHRA in developing and implementing the appropriate mechanisms to support this process. Therapies which fall under approved international recognition routes will be eligible for accelerated use within the NHS.   With the number of accelerated approvals set to increase, the need for long term post approval data collection is anticipated to increase, meaning that the right partner to support both patients and evidence generation will become a core part of how to launch medicines in the future, 

At Bionical Health, we specialise in delivering tailored solutions that ensure the success of your approach to the UK market. Our team understands the complexities of real-world evidence generation and the critical role skilled professionals play in every phase, from solution design to patient access, patient retention and data analysis. We provide experienced, fully compliant staff, ensuring that every programme is executed efficiently and to the highest standards. 

Our flexible approach and close working relationships with the NHS at national and ocal level allows us to meet the unique needs of each circumstance, whether it requires short-term support or long-term collaboration. We work closely with clients to ensure our team integrates seamlessly into existing teams, helping to optimize timelines and reduce delays. Our teams are skilled in the handling and administration of IP and its associated logistical chain whilst at all times maintaining adherence to regulatory requirements. At Bionical Health, our goal is to market leading clinical solutions that drive innovation and bring life-changing therapies to patients faster.